Clinical History, Skin Prick Test and RAST in the Diagnosis of Birch and Timothy Pollinosis

The diagnostic efficacy of clinical history (CH), skin prick test (SPT) and RAST was estimated in relation to nasal and conjunctival provocation tests (NPT, CPT) in 69 patients with seasonal rhinoconjunctivitis. The extracts used were freeze-dried, and biologically standardized birch and timothy allergen preparations matched to the extracts on Phadebas RAST discs. Based on single determinations the sensitivity, specificity and predictive values were calculated. There were highly significant (P less than 0.001) correlations between all parameters: NPT, CPT, CH, SPT and RAST. For birch the combination of SPT and RAST made the PTs superfluous as both sensitivity and specificity then reached 100%. With timothy the sensitivity was 97% and with the addition of CH 100%. However, the specificity was only 79% through combining CH, SPT and RAST. The present study using the same standardized allergen preparation in all tests showed a good correlation between indirect test results and provocation tests.     

鼻内镜下等离子低温射频治疗常年性变应性鼻炎的临床观察

目的探讨鼻内镜下等离子低温射频治疗常年性变应性鼻炎(PAR)的疗效及其优越性。方法在鼻内镜下用等离子低温射频治疗PAR48例,按照海口会议修订的“过敏性鼻炎诊断和疗效评定标准”,用计分法分别评定其疗效。结果该组48例术后随访半年进行评价,其中显效27.1%(13/48),有效58.3%(28/48),无效14.6%(7/48),总有效率为85.4%。疗效评分显示治疗前平均总分为(9.58±1.69)分,治疗后为(5.63±1.15)分(P<0.05)。结论鼻内镜下等离子低温射频烧灼筛前神经终末区域治疗PAR,具有简便、安全等优点,短期效果显著,特别适用于临床上应用抗组胺类药物及鼻内应用糖皮质激素治疗效果不甚理想及由于各种原因不能长期接受抗组胺类药物及鼻内应用糖皮质激素治疗的患者;但长期疗效有待进一步研究。     

Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis

BACKGROUND: Rofleponide palmitate is an esterified glucocorticosteroid pro-drug with a promising pre-clinical profile designed to deliver topical airway treatment for allergic rhinitis and asthma in a novel manner. Thus, the rofleponide palmitate pro-drug is designed to provide topical exposure of the mucosa to the inactive lipophilic drug, which would be locally metabolized to the more hydrophilic and readily cleared drug rofleponide. OBJECTIVE: To examine whether rofleponide palmitate affects nasal symptoms and peak inspiratory flow (PIF) in a pollen-season model of allergic rhinitis and to compare any such effects with those of another glucocorticosteroid (i.e., budesonide). METHODS: During the pollen-free season, 40 patients with strictly seasonal allergic rhinitis received topical nasal spray treatment with an aqueous solution of rofleponide palmitate 400 microg and an aqueous solution of budesonide 128 microg once daily for 10 days in a double-blind, placebo-controlled, and crossover study. After 3 days of drug treatment, individualized allergen challenges were given once daily for 7 days while the treatment continued. The washout periods between each of the challenge series were 2 weeks. Nasal symptoms and PIF were recorded in the morning and evening, as well as 10 and 20 min after each allergen challenge. The mean recordings obtained during the last 3 days of the allergen-challenge series, when symptoms were established and when the treatment had lasted for 8-10 days, were used in the analysis. RESULTS: Both active treatments reduced nasal symptoms and improved nasal PIF compared with placebo (P<0.01-0.001). There was no overall difference in efficacy between rofleponide palmitate 400 microg and budesonide 128 microg. CONCLUSIONS: Topical treatment with aqueous solutions of rofleponide palmitate attenuates nasal symptoms and improves nasal PIF in allergic rhinitis. The overall efficacy of 400 microg of rofleponide palmitate is similar to that of 128 microg of budesonide in the pollen-season model used in this study.     

慢性阻塞性肺疾病的肺生物学标记物研究进展

与慢性阻塞性肺疾病（COPD）有关的很多炎症细胞、介质,正逐渐为人们所熟知。本文讨论支气管活组织切片、痰液、支气管肺泡灌洗液、呼出气凝物等方面的有关生物标记在COPD研究中的进展。     

Reversible and irreversible airway inflammation and fibrosis in mice exposed to inhaled ovalbumin

Objective and design: We examined the reversibility of several changes in the lungs and airways of mice immediately after exposure to ovalbumin aerosol and after a period of recovery breathing clean air.Methods: Mice were exposed for 1, 2, 4, 6, 8, or 10 weeks, with recovery in clean air for 1–3 weeks.Results: Airway collagen content, exhaled NO, airway mucous cell hyperplasia, and lung lavage inflammatory cell content increased upon exposure to ovalbumin aerosol. All parameters except airway fibrosis decreased partially or completely to control values with recovery in clean air.Conclusions: Airway mucous cell hypertrophy and hyperplasia appear to be completely reversible after recovery in clean air, while exhaled NO and airway inflammation appear to be mostly reversible, except for persistence of lymphocytes in the lung lavage fluid. Airway fibrosis appears to be reversible when mice are exposed to ovalbumin aerosol for periods of up to 4 weeks of exposure, but becomes irreversible after 6 or more weeks of exposure.Received 30 June 2004; returned for revision 24 September 2004; accepted by J. S. Skotnicki 13 October 2004     

治疗老年重症呼吸衰竭42例临床分析

目的：探讨机械通气联合支气管肺泡灌洗（BAL）在治疗老年重症呼吸衰竭的作用。方法：选择常规治疗后病情无缓解的重症老年呼吸衰竭患者42例。建立人工气道行钡械通气治疗12～24h后，低氧血症纠正不理想，气道压力偏高，痰多者，应用加温至37℃生理盐水加庆大霉素、地塞米松及爱全乐经纤支镜行BAL，吸除呼吸道粘稠分泌物，每日一次，连续3—5天。结果：42例患者中，37例通气24h，经支气管肺泡灌洗后，气道压力下降，临床症状好转，缺氧及二氧化碳滞留得到改善，病原菌得到明确，成功脱机出院。结论：对老年重症呼吸衰竭在机械通气的基础上联合支气管肺泡灌洗是治疗呼吸衰竭安全有效的重要措施，值得临床应用。     

极低出生体重儿两种喂养效果观察

目的:探讨极低出生体重儿(VLBW)的早期微量持续鼻饲喂养(CNG)与间断鼻饲喂养(ING)的喂养耐受性及喂养效果.方法:将60例VLBW进行随机分组,CNG组起始奶量1-2ml/h,以后泵速增加1-2ml/h.ING组奶量以1-2ml/kg开始, 以后每天增加1-2ml/kg/次.所有VLBW均同时进行部分静脉营养,直至达到完全胃肠道喂养时间(FEF).对比两组喂养不耐受性、达到FEF、停止静脉补液时间及黄疸持续时间.结果:CNG组较ING组患儿发生腹胀、呕吐者明显减少(P＜0.05),黄疸持续时间、吸吮动作出现时间及住院时间较对照组明显缩短(P＜0.05),但两组体重增长情况统计学无差异(P＞0.05).结论:CNG更适合VLBW的早期微量喂养.     

Human Herpesvirus 6 in Bronchalveolar Lavage Fluid after Lung Transplantation: A Risk Factor for Bronchiolitis Obliterans Syndrome?

Bronchiolitis obliterans syndrome (BOS) is the limiting factor to long-term survival after lung transplantation. Previous studies suggested respiratory viral tract infections are associated with the development of BOS. To identify the impact of virus detection in bronchoalveolar lavage (BAL) fluid, we analyzed BAL samples from 87 consecutive lung transplant recipients for human herpesvirus (HHV)-6, Epstein-Barr virus, Herpes simplex virus 1/2, Cytomegalovirus, respiratory syncytical virus and adenovirus by PCR. Acute rejection, BOS and death were recorded for a mean follow-up time of 3.27 +/- 0.47 years. Results of PCR analysis and other potential risk factors were entered into a Cox regression analysis of BOS predictors and death. Only acute rejection was a distinct risk factor for BOS of all stages, death and death from BOS. HHV-6 was detected in 20 patients. Univariate and multivariate analysis revealed that HHV-6 was associated with an increased risk to develop BOS > orb = stage 1 and death, separate from the risk attributable to acute rejection. Identification of HHV-6 DNA in BAL fluid is a potential risk factor for BOS. Our results warrant further studies to elucidate a possible causal link between HHV-6 and BOS.